佛慈制药(002644) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥274,329,503.97, representing a decrease of 13.85% compared to ¥307,394,758.83 in the same period last year[5] - Net profit attributable to shareholders was ¥18,387,224.27, down 23.11% from ¥27,454,528.98 year-over-year[5] - Basic and diluted earnings per share decreased by 23.08% to ¥0.0360 from ¥0.0538 in the same period last year[5] - Net profit for Q1 2024 was CNY 18,641,576.17, representing a decline of 21.93% from CNY 23,903,831.70 in Q1 2023[19] - Total operating revenue for Q1 2024 was CNY 274,329,503.97, a decrease of 13.83% compared to CNY 318,446,773.30 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was -¥16,074,451.17, a significant decline of 306.33% compared to -¥3,956,040.69 in the previous year[11] - The company's cash flow from operating activities showed a significant improvement, with a net cash inflow of CNY 22,999,318.64 in Q1 2024 compared to CNY 30,151,744.30 in Q1 2023[19] - Total cash inflow from operating activities is 179,828,915.87 yuan, down 35.4% from 277,840,595.03 yuan in the previous period[21] - Cash outflow from operating activities is 195,903,367.04 yuan, a decrease of 30.5% compared to 281,796,635.72 yuan in the previous period[21] - The cash flow from operating activities has shown a concerning trend with a net outflow, which may impact future liquidity[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,527,502,345.91, a slight decrease of 0.02% from ¥2,528,102,214.36 at the end of the previous year[5] - Total liabilities decreased to CNY 740,430,835.25 in Q1 2024 from CNY 759,672,279.87 in Q1 2023, reflecting a reduction of 2.93%[17] - The company's cash and cash equivalents decreased to ¥365,338,610.71 from ¥406,040,604.70 at the beginning of the period, a decline of approximately 10.5%[15] - Total current assets amounted to ¥1,252,844,935.25, up from ¥1,238,869,322.84, reflecting a growth of about 1.1%[15] Investment and Expenses - Investment income showed a significant decline of 525.78%, resulting in a loss of -¥2,609,200.00 compared to a profit of ¥612,806.13 in the previous year[10] - Financial expenses decreased by 58.87% to -¥446,907.81, primarily due to adjustments in bank deposit interest rates[10] - Research and development expenses for Q1 2024 were CNY 6,885,069.00, an increase from CNY 6,295,170.51 in the previous year, indicating a focus on innovation[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,759[13] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, holds 61.63% of the shares, totaling 314,713,676 shares[13] - The total equity attributable to shareholders of the parent company increased to CNY 1,763,758,032.04 in Q1 2024 from CNY 1,745,370,807.77 in Q1 2023, reflecting a growth of 1.05%[17] Other Information - The company has not disclosed any new product developments or technological advancements in the current report[14] - There are no significant changes in the top 10 shareholders' participation in margin trading or securities lending[14] - The company has not reported any mergers or acquisitions during this period[14] - No new strategic initiatives have been mentioned in the current financial report[14] - The first quarter report has not been audited, which may affect the reliability of the financial data presented[23]